Valuation ... Another interesting exampleIt's always interesting to see the valuation some biotechs get when their technologies start showing potential.
Here's another perfect example. ACLX is now valued at approx. 807M$US, 15.5x more than TLT's current US value (52M$US). It was IPOed at 600M$US in Feb. 2022.
Multiple Myeloma is a blood disorder.
Solid tumors always get a much higher valuation than blood cancers. If TLT gets clear positive data at its next update, that should capture some interest, so influence its market valuation. We are so priviledged to have TLT listed on an exchange at this ridicule valuation, if we're to become a standard of care. We are so undervalued!
See some similarities, in terms of efficacy %, disruptive technology, market shares, etc ...:
How Newcomer Arcellx Is Looking To Rival Johnson & Johnson In Cancer 06/06/2022 Newcomer Arcellx (ACLX) could rival Johnson & Johnson (JNJ) in multiple myeloma, an analyst said Monday as the biotech stock soared to a two-month high.
Arcellx tested tailor-made cancer drugs, known as
CAR-T, in patients
with advanced multiple myeloma. Every patient responded, and all signs of cancer disappeared in 71% of patients who could be evaluated. "Pretty much any way you slice the updated data, (Arcellx's treatment's effectiveness) outcomes are in line with the class-leader, J&J's Carvykti," SVB Securities analyst Daina Graybosch said in a report. On today's stock market, the biotech stock surged 20.6% to 15.79. J&J and Legend shares closed roughly flat at a respective 176.40 and 46.
Biotech Stock: Genetically Modified Cancer Fighters CAR-T drugs use a patient's own immune cells, genetically modified to attack cancer. The leader in this space is Carvykti from Johnson & Johnson and Legend Biosciences (LEGN). Arcellx evaluated 31 patients following at least one month of treatment with its drug. All patients had poor prognoses and were considered difficult to treat. Nearly all of the patients, 94%, had a "very good" partial response to the treatment. 16 patients received treatment more than a year ago. Out of that group, 13 showed no detectable signs of cancer and 9 are still responding at a median of 17.7 months. Bullishly for biotech stock Arcellx, there have also been no serious cases of cytokine release syndrome, a common side effect of CAR-T treatment, which riles up the immune system. Physicians managed those episodes with standard treatment, Arcellx said in its news release.
Initial Public Offering In February Arcellx launched its initial public offering in February (600M$US) and closed its first trading day at 16.80$.
But shares recently surged above their 50-day moving line, according to MarketSmith.com.
SVB Securities' Graybosch has an outperform rating on the biotech stock.